Pfizer Inc is planning to raise $31 billion through its largest debt offering to finance its proposed acquisition of Seagen Inc , the drugmaker said late on Tuesday.
a $43 billion deal in March to acquire Seagen and its targeted cancer therapies as it prepares for a steep fall in COVID-19 sales and generic competition for some top-selling drugs.had in 2019 made a $30 billion debt offering, which was used to finance its $63 billion buyout of Botox maker Allergan. The amount is more than double that of Pfizer's 2009 debt raise of $13.5 billion.
The debt offering, which would be in eight tranches, is expected to close on May 19. Yield to maturity on Pfizer's 10-year bonds would be 125 basis points higher than the benchmark risk-free U.S. 10-year Treasury .
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer to raise $31 bln for Seagen takeover in largest debt offeringPfizer Inc is planning to raise $31 billion through its largest debt offering to finance its proposed acquisition of Seagen Inc , the drugmaker said late on Tuesday.
Read more »
Pfizer borrows $31 billion in mega bond deal as debt issuance picks up ahead of debt-ceiling deadlinePharmaceutical giant Pfizer secures $31 billion in financing on Tuesday, as companies pick up the borrowing pace ahead of a June U.S. debt-ceiling deadline.
Read more »
Megabank stocks rise in premarket as Pfizer deal boosts underwritingStocks for the largest U.S. banks rose in premarket trades on Wednesday, amid an uptick in underwriting activity following a $31 billion debt offering from...
Read more »
Opinion: What's behind American media's unhealthy fixation on 'Mormons, Inc.'?In a broadcast that aired Sunday, the CBS television program
Read more »
PolitiFact - Pfizer’s $2.3 billion settlement was not related to COVID-19 vaccinesPfizer paid a $2.3 billion health care fraud settlement, but it was in 2009 and for an anti-inflammatory drug called Bextra. It was more than a decade before the COVID-19 pandemic.
Read more »
Pfizer RSV Vaccine for Infants Has ‘Generally Favorable' Safety Data, FDA Staff SayThe FDA is slated to make a decision on whether to approve Pfizer’s shot in August before respiratory syncytial virus season in the fall.
Read more »